Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery

Inclusion Criteria: * Patients of both sexes, in the age group: ≥18 and ≤80 years. * Patients diagnosed with confirmation of severe knee osteoarthritis according to Kellgren criteria (equal or greater than 2) and EVA greater than 7, who will be subjected to knee arthroplasty surgery. * Patients signing informed consent, agreeing to participate in the study. Exclusion Criteria: * Patients with concomitant cardiac disease: unstable angina pectoris, acute myocardial infarction, atrial fibrillation, flutter, history of sudden death, severe valve insufficiency. * Patients with concomitant previous thromboembolic disease: Deep venous thrombosis, pulmonary thromboembolism, thrombotic arterial embolism, Ischemic Vascular Cerebral Stroke, fibrinolytic diseases after consumption coagulopathy. * Hypersensitivity to tranexamic acid. * Severe systemic disease: cardio-pulmonary, neurological, renal, infectious or any other type that may impede the development of the study or evaluation of the results. * History of seizures. * Patients with severe mental disorder (psychotic disorder, risk of autolysis, manic episode), dependence on toxic substances and / or some physical or psychological limitation to answer. * Patients receiving oral anticoagulants. * Patients in litigation for disability claim related or not with the disease. * Patients who cannot make the necessary visits to carry out the study. * Patients who refuse to participate or sign informed consent. * Pregnant and lactating patient's period.